Drug Trial Radar · NCT02623699
An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)
Last checked: Nov 20, 2026Latest source record: Jul 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
176
Actual
Start
Jan 20, 2016
Primary completion
Jul 16, 2021
Study completion Jul 16, 2021
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- Collaborators
- Ionis Pharmaceuticals, Inc.
- First posted
- Dec 8, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of Parts A and B of this study are to evaluate the safety, tolerability, and pharmacokinetics (PK) of ascending doses of tofersen in adults with ALS and a documented superoxide dismutase 1 (SOD1) mutation. The primary objective of Part C of this study is to evaluate the clinical efficacy of tofersen administered to adults with ALS and a confirmed SOD1 mutation. The secondary objective of Parts A and B of this study is to evaluate the effects of tofersen on levels of total SOD1 protein in the cerebrospinal fluid (CSF). The secondary objectives of Part C are to evaluate the safety, tolerability, pharmacodynamic (PD), and biomarker effects of tofersen.
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
TofersenDrug
Administered as specified in the treatment arm.
PlaceboDrug
Administered as specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts A and B: Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Part A: First dose up to Day 63; Part B: First dose up to Day 289
- Parts A and B: Number of Participants With Clinically Significant Laboratory AbnormalitiesTime frame: Part A: Up to Day 57; Part B: Up to Day 169
- Parts A and B: Number of Participants With Clinically Significant Vital Sign AbnormalitiesTime frame: Part A: Up to Day 57; Part B: Up to Day 169
- Parts A and B: Number of Participants With Clinically Significant Physical Examination AbnormalitiesTime frame: Part A: Up to Day 57; Part B: Up to Day 169
- Parts A and B: Number of Participants With Clinically Significant Neurological Examination AbnormalitiesTime frame: Part A: Up to Day 57; Part B: Up to Day 169
- Parts A and B: Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) AbnormalitiesTime frame: Part A: Up to Day 57; Part B: Up to Day 169
- Parts A and B: PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)Time frame: Part A: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1; Part B: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1 and 1, 2, 4, 6 hrs post-dose on Day 85
- Parts A and B: PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)Time frame: Part A: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1; Part B: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1 and 1, 2, 4, 6 hrs post-dose on Day 85
- Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24h)Time frame: Parts A and B: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1
- Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)Time frame: Part A: Pre-dose Day 1, Days 29 and 57; Part B: Pre-dose Days 1, 15, 29, 57 and 85; Day 106 and 169
- Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)Time frame: Part A: Pre-dose Day 1, Days 29 and 57; Part B: Pre-dose Days 1, 15, 29, 57 and 85; Day 106 and 169
- Parts A and B: PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)Time frame: Part A: Pre-dose Day 1, Days 29 and 57; Part B: Pre-dose Days 1, 15, 29, 57 and 85; Day 106 and 169
- Parts A and B: PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)Time frame: Part A: Pre-dose Day 1, Days 29 and 57; Part B: Pre-dose Days 1, 15, 29, 57 and 85; Day 106 and 169
- Part C: Change From Baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Total Score at Week 28Time frame: Baseline, Week 28 (Day 197)
Locations
40 sites in 12 countries. Site status is shown where the registry gives one.
Barrow Neurological Institute
Phoenix, Arizona
University of California San Diego Medical Center
La Jolla, California
California Pacific Medical Center
San Francisco, California
Mayo Clinic in Florida
Jacksonville, Florida
University of Miami School of Medicine
Miami, Florida
Bioclinica Research
Orlando, Florida
Emory University Hospital
Atlanta, Georgia
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Johns Hopkins University
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Henry Ford Hospital
Detroit, Michigan
Mayo Clinic - Rochester
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
Neurology Associates, P.C.
Lincoln, Nebraska
Columbia University Medical Center
New York, New York
The Cleveland Clinic Foundation
Cleveland, Ohio
Providence ALS Center
Portland, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
New Orleans Center for Clinical Research/Volunteer Research Group, an AMR Company
Knoxville, Tennessee
Methodist Neurological Institute
Houston, Texas
Westmead Hospital
Westmead, New South Wales, Australia
UZ Leuven
Leuven, Belgium
University of Calgary - Health Sciences Centre
Calgary, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Montreal Neurological Institute
Montreal, Quebec, Canada
Bispebjerg Hospital
Copenhagen, Denmark
Hopital Pitie Salpetriere
Paris, France
University of Ulm
Ulm, Baden-Wurttemberg, Germany
ALS Center - Dept. of Neuroscience "Rita Levi Montalcini", University of Turin
Torino, Italy
The University of Tokyo Hospital
Bunkyō City, Japan
Research Site
Fukuoka, Japan
Research Site
Kagoshima, Japan
Research Site
Shinjuku-ku, Japan
Research Site
Suita-Shi, Japan
Research Site
Warsaw, Poland
Research Site
Seoul, South Korea
Research Site
Yangsan, Gyeongsangnam-do, South Korea
Research Site
London, Greater London, United Kingdom
Research Site
Sheffield, South Yorkshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.